Gilteritinib overcomes second‑generation TKIs resistance in ALK‑rearranged non‑small‑cell lung cancer by inhibiting PD‑L1 and CD8 co‑expression
Hang Guo(Second Affiliated Hospital of Jilin University), Chunguang Wang(Second Affiliated Hospital of Jilin University), Chengyan Jin(Second Affiliated Hospital of Jilin University), Yaoji Li(Jilin Province Tumor Hospital), Jincheng Wang(Second Affiliated Hospital of Jilin University), Xiao Qi(Second Affiliated Hospital of Jilin University), Baofeng Li(Second Affiliated Hospital of Jilin University)
Cited by 0
Related Papers
The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation
|Journal of Neuroinflammation|2018|207
The Appropriate Marker for Astrocytes: Comparing the Distribution and Expression of Three Astrocytic Markers in Different Mouse Cerebral Regions
|BioMed Research International|2019|168
Evaluating the effects of mobile health intervention on weight management, glycemic control and pregnancy outcomes in patients with gestational diabetes mellitus
|Journal of Endocrinological Investigation|2018|157